With our team of experienced personnel and state-of-the-art technology, we are the premier CRO of choice in Australia offering a full suite of services in-house.

CPR's clinical and data capabilities cover all phases and therapeutic areas of drug development with bioanalytical laboratory support for the development and analysis of small and large molecules.

  • Operates as an efficient multiservice CRO
  • Collaborates with clinical Phase I sites
    • All co-located in Institutions: access to patients in line with their specialities, including oncology
  • Strong experience in both early and late stage studies
  • Synergy of services: Clinical and Bioanalytical
  • Demonstrated history of success and reputation
  • EMA and FDA inspected
 CPR Pharma 2016

The Australian Advantage

Located in Adelaide, South Australia, the birth place of early phase clinical research in the region, CPR has extensive experience working with clients to access Australia's:

 

Our Customers

CPR's client portfolio includes:

  • Small biotech
  • Small-medium pharma
  • Large pharma
  • Repeat work rate >80%
    • >70% of sales from USA
    • 20% from Australia/NZ
    • ~ 10% other
The CPR Journey CPR Pharma 2016

The CPR Journey

CPR had its genesis in the University of South Australia in the early 1980s as the Centre for Pharmaceutical Research when a group of academic scientists began providing clinical trial and bioanalytical services to the local pharmaceutical industry.

Since then we have steadily grown to become a significant Australian Contract Research Organisation, servicing both the local and international drug development industry.

In 2009 CPR Pharma Services Pty Ltd was incorporated and commenced operating independently of the University of South Australia.  With an experienced management team and senior staff backed by some of Australia’s leading pharmaceutical industry consultants, CPR has developed a reputation as a reputable provider of clinical study managementdata/biostatistical services, and bioanalytical services.

Join us on